文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非酒精性脂肪性肝病和代谢相关脂肪性肝病的结局:一项基于社区的前瞻性队列研究结果。

Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study.

机构信息

Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka.

National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo, Japan.

出版信息

PLoS One. 2021 Feb 3;16(2):e0245762. doi: 10.1371/journal.pone.0245762. eCollection 2021.


DOI:10.1371/journal.pone.0245762
PMID:33534815
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7857550/
Abstract

BACKGROUND: The term "metabolic (dysfunction)-associated fatty liver disease" (MAFLD) is suggested alternative for "non-alcoholic fatty liver disease" (NAFLD), as it better reflects metabolic dysfunction. No study has compared outcomes of the two diagnostic criteria. METHODS: In an ongoing, community-based, cohort-study in suburban Sri Lanka, participants were randomly selected in 2007. They were reassessed in 2014 to evaluate new-onset metabolic traits (MTs) and cardiovascular-events (CVEs). Baseline characteristics, MTs and CVEs after 7-years were compared in NAFLD and MAFLD and vs. controls. Similarly, we compared these parameters in those excluded by the NAFLD definition but captured by the MAFLD definition and vice versa, and vs. controls. FINDINGS: Of 2985 recruited in 2007, 940 (31.5%) had NAFLD, 990 (33.1%) had MAFLD and 362 (12.1%) were controls. When compared to NAFLD, MAFLD captured an additional 2.9% and lost 1.3% individuals. At baseline, anthropometric and metabolic traits were similar in NAFLD and MAFLD. At follow-up in 7-years, the risk of having new-onset MTs and fatal/non-fatal CVEs were similar in the groups, but were significantly higher compared to controls. Those excluded by the NAFLD definition but captured by the MAFLD definition showed higher baseline MTs compared to those excluded by the MAFLD definition but captured by the NAFLD definition, and had substantially higher risk for having new-onset MTs and CVEs compared to controls. INTERPRETATION: Although NAFLD and MAFLD had similar MTs at baseline, and similar outcomes after 7-years, those who were excluded by the NAFLD definition but captured by the MAFLD definition seem at higher risk of adverse outcomes than those excluded by the MAFLD definition but captured by the NAFLD definition. Although the increase in the index population was small, redefining NAFLD as MAFLD seemed to improve clinical utility.

摘要

背景:代谢相关脂肪性肝病(MAFLD)这一术语是对非酒精性脂肪性肝病(NAFLD)的替代,因为它更好地反映了代谢功能障碍。目前尚无研究比较这两种诊断标准的结果。

方法:本研究为正在进行的、基于社区的斯里兰卡郊区队列研究,于 2007 年随机选择参与者。2014 年对他们进行了重新评估,以评估新出现的代谢特征(MTs)和心血管事件(CVE)。比较了基线特征、7 年后的 MTs 和 CVE 在 NAFLD 和 MAFLD 患者与对照组之间的差异。同样,我们比较了那些被 NAFLD 定义排除但被 MAFLD 定义捕获的患者与对照组之间的差异,反之亦然。

结果:在 2007 年招募的 2985 名患者中,940 名(31.5%)患有 NAFLD,990 名(33.1%)患有 MAFLD,362 名(12.1%)为对照组。与 NAFLD 相比,MAFLD 多捕捉了 2.9%的患者,少捕捉了 1.3%的患者。在基线时,NAFLD 和 MAFLD 患者的人体测量学和代谢特征相似。在 7 年的随访中,新发生 MTs 和致命/非致命 CVE 的风险在各组中相似,但明显高于对照组。那些被 NAFLD 定义排除但被 MAFLD 定义捕获的患者,其基线 MTs 高于那些被 MAFLD 定义排除但被 NAFLD 定义捕获的患者,与对照组相比,新发生 MTs 和 CVE 的风险显著更高。

解释:虽然 NAFLD 和 MAFLD 在基线时的 MTs 相似,且 7 年后的结果相似,但那些被 NAFLD 定义排除但被 MAFLD 定义捕获的患者的不良结局风险似乎高于那些被 MAFLD 定义排除但被 NAFLD 定义捕获的患者。尽管纳入人群的增加很小,但将 NAFLD 重新定义为 MAFLD 似乎提高了临床实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dad/7857550/c8c00eec6980/pone.0245762.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dad/7857550/c8c00eec6980/pone.0245762.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dad/7857550/c8c00eec6980/pone.0245762.g001.jpg

相似文献

[1]
Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study.

PLoS One. 2021

[2]
Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.

World J Gastroenterol. 2023-1-21

[3]
The clinical utility of accurate NAFLD ultrasound grading: Results from a community-based, prospective cohort study.

Eur J Radiol. 2021-3

[4]
Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.

J Gastroenterol Hepatol. 2022-2

[5]
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.

J Hepatol. 2021-12

[6]
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.

Cardiovasc Diabetol. 2022-12-3

[7]
New definition of metabolic dysfunction-associated fatty liver disease with elevated brachial-ankle pulse wave velocity and albuminuria: a prospective cohort study.

Front Med. 2022-10

[8]
Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.

Int J Environ Res Public Health. 2021-8-26

[9]
Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.

Clin Gastroenterol Hepatol. 2021-10

[10]
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

Clin Mol Hepatol. 2021-4

引用本文的文献

[1]
Xietu Hemu Prescription Improves Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Cohort Study.

J Multidiscip Healthc. 2025-7-29

[2]
Clinical and Biochemical Features of Diagnosed and Undiagnosed Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.

Can Liver J. 2025-3-28

[3]
Comparative association between NAFLD and MAFLD with cardiovascular events and mortality: Evidence from observational studies.

PLoS One. 2025-6-13

[4]
Metabolic dysfunction-associated fatty liver disease indicates more hepatic fibrosis than nonalcoholic fatty liver disease.

Medicine (Baltimore). 2025-2-7

[5]
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.

Hepatol Int. 2024-12

[6]
Impact of Nonalcoholic Hepatic Steatosis on the Warranty Period of a Coronary Artery Calcium Score of 0: Results From the Multi-Ethnic Study of Atherosclerosis.

Circ Cardiovasc Imaging. 2024-9

[7]
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals.

Hepatol Int. 2024-10

[8]
The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD.

Rev Cardiovasc Med. 2023-5-31

[9]
Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography.

J Cachexia Sarcopenia Muscle. 2024-10

[10]
Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.

Abdom Radiol (NY). 2024-9

本文引用的文献

[1]
From NAFLD to MAFLD: Implications of a Premature Change in Terminology.

Hepatology. 2021-3

[2]
Comparison of MAFLD and NAFLD diagnostic criteria in real world.

Liver Int. 2020-9

[3]
What's in a name? Renaming 'NAFLD' to 'MAFLD'.

Liver Int. 2020-6

[4]
Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China.

Int J Environ Res Public Health. 2020-3-11

[5]
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.

Gastroenterology. 2020-5

[6]
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.

Gastroenterology. 2020-5

[7]
Metabolic syndrome, but not non-alcoholic fatty liver disease, increases 10-year mortality: A prospective, community-cohort study.

Liver Int. 2020-1

[8]
Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD).

Medicine (Baltimore). 2018-3

[9]
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Nat Rev Gastroenterol Hepatol. 2017-9-20

[10]
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

J Hepatol. 2017-8-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索